Acadian Asset Management LLC Buys 27944 Shares of Systemax Inc. (SYX)

Systemax logo Acadian Asset Management LLC boosted its position in Systemax Inc. (NYSE:SYX) by 85.6% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 60,599 shares of the company’s stock …

Systemax logoAcadian Asset Management LLC boosted its position in Systemax Inc. (NYSE:SYX) by 85.6% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 60,599 shares of the company’s stock after purchasing an additional 27,944 shares during the quarter. Acadian Asset Management LLC owned approximately 0.16% of Systemax worth $2,018,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of SYX. Wells Fargo & Company MN boosted its position in shares of Systemax by 0.7% during the second quarter. Wells Fargo & Company MN now owns 6,846 shares of the company’s stock valued at $129,000 after buying an additional 45 shares during the last quarter. Rhumbline Advisers boosted its position in Systemax by 0.6% in the second quarter. Rhumbline Advisers now owns 15,372 shares of the company’s stock worth $289,000 after purchasing an additional 88 shares during the last quarter. TIAA CREF Investment Management LLC boosted its position in Systemax by 0.9% in the second quarter. TIAA CREF Investment Management LLC now owns 55,467 shares of the company’s stock worth $1,043,000 after purchasing an additional 513 shares during the last quarter. Alliancebernstein L.P. boosted its position in Systemax by 12.1% in the second quarter. Alliancebernstein L.P. now owns 14,807 shares of the company’s stock worth $278,000 after purchasing an additional 1,600 shares during the last quarter. Finally, Nisa Investment Advisors LLC purchased a new position in Systemax in the fourth quarter worth about $153,000. Hedge funds and other institutional investors own 26.66% of the company’s stock.

Separately, Sidoti downgraded Systemax from a “buy” rating to a “neutral” rating in a research note on Friday, November 10th.

Shares of Systemax Inc. (NYSE:SYX) traded up $0.30 on Wednesday, reaching $30.25. The company had a trading volume of 35,067 shares, compared to its average volume of 100,210. Systemax Inc. has a 52 week low of $7.05 and a 52 week high of $34.91. The company has a market cap of $1,138.47, a P/E ratio of 302.53 and a beta of 0.11.

COPYRIGHT VIOLATION WARNING: “Acadian Asset Management LLC Buys 27,944 Shares of Systemax Inc. (SYX)” was originally published by Week Herald and is the property of of Week Herald. If you are viewing this piece of content on another website, it was copied illegally and republished in violation of international copyright & trademark legislation. The original version of this piece of content can be accessed at https://weekherald.com/2018/02/21/systemax-inc-syx-shares-bought-by-acadian-asset-management-llc.html.

About Systemax

Systemax Inc is a direct marketer of brand name and private label products. The Company’s segments are Industrial Products Group (IPG), EMEA Technology Products Group (EMEA), and Corporate and Other (Corporate). The IPG segment sells an array of maintenance, repair and operational (MRO) products, which are marketed in North America.

Institutional Ownership by Quarter for Systemax (NYSE:SYX)

Receive News & Ratings for Systemax Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Systemax and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

FNF Group of Fidelity National Financial, Inc. (FNF) Shares Bought by PGGM Investments

FNF Group of Fidelity National Financial logo PGGM Investments grew its stake in shares of FNF Group of Fidelity National Financial, Inc. (NYSE:FNF) by 115.5% in the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 1,120,700 shares of the financial services …

Related Posts:

  • No Related Posts

MagneGas (MNGA) Sees Strong Trading Volume

Renaissance Technologies LLC lifted its stake in MagneGas Co. (NASDAQ:MNGA) by 22.7% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 356,244 shares of the oil and gas company’s stock after acquiring an additional 65,900 shares …

MagneGas logoShares of MagneGas Co. (NASDAQ:MNGA) saw unusually-high trading volume on Wednesday . Approximately 5,102,072 shares were traded during mid-day trading, an increase of 738% from the previous session’s volume of 609,113 shares.The stock last traded at $1.22 and had previously closed at $1.17.

The company has a debt-to-equity ratio of 0.08, a quick ratio of 0.26 and a current ratio of 0.70. The firm has a market capitalization of $2.30, a P/E ratio of -0.04 and a beta of -1.01.

In related news, Director Carla Santilli sold 108,334 shares of the firm’s stock in a transaction that occurred on Friday, January 12th. The stock was sold at an average price of $0.31, for a total value of $33,583.54. Following the transaction, the director now directly owns 375,199 shares of the company’s stock, valued at approximately $116,311.69. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 4.45% of the stock is currently owned by company insiders.

A hedge fund recently raised its stake in MagneGas stock. Renaissance Technologies LLC lifted its stake in MagneGas Co. (NASDAQ:MNGA) by 22.7% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 356,244 shares of the oil and gas company’s stock after acquiring an additional 65,900 shares during the period. Renaissance Technologies LLC owned 20.36% of MagneGas worth $114,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 39.68% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “MagneGas (MNGA) Sees Strong Trading Volume” was first published by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this piece of content on another publication, it was illegally copied and reposted in violation of U.S. and international copyright & trademark laws. The legal version of this piece of content can be accessed at https://stocknewstimes.com/2018/02/21/magnegas-mnga-sees-strong-trading-volume.html.

About MagneGas

MagneGas Corporation is an alternative energy company. The Company creates and produces hydrogen-based alternative fuel through the gasification of carbon-rich liquids, including certain liquids and liquid wastes. The Company is also developing the use of fuel for co-combustion with hydrocarbon fuels to reduce emissions.

Receive News & Ratings for MagneGas Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for MagneGas and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

Revenue Estimates Analysis Zion Oil & Gas, Inc. (ZN)

3D Systems Corporation (DDD) stock price traded at a gap of -0.09% from an average price of last twenty days and stands at a distance of 2.87% away from it’s an average price of recent fifty days. Goldman Sachs upgraded Carrizo Oil & Gas, Inc. (NASDAQ:CRZO) has declined 34.05% since February …

The company has market cap of $789.10 million. It has a 106.39 P/E ratio. Frontier Capital Management Co.

Judging by the trade P Johnson made he is in the bear’s eye today. Advisor Group Inc. now owns 8,121 shares of the oil and gas producer’s stock valued at $141,000 after purchasing an additional 2,611 shares during the period. Moreover, Comerica National Bank & Trust has 0.01% invested in Aegion Corporation (NASDAQ:AEGN) for 34,912 shares. It is up 16.78% since February 20, 2017 and is uptrending. A report filed with the U.S. Security and Exchange Commission and available for a free review here, discloses extra info for the deal. Jefferies maintained the shares of CRZO in report on Tuesday, August 29 with “Buy” rating.

Analysts are expecting average earnings estimates of $0.57 for the current quarter based on the opinion of 24 analysts, relating to high earnings per share estimates of $0.92 and low estimates of $0.43, however Carrizo Oil & Gas (NASDAQ:CRZO) reported $0.44 earnings per share for the same quarter previous year. Carrizo Oil & Gas Inc now has $1.46B valuation. Therefore 100% are positive. The stock of Century Communities, Inc. The volatility in the previous week has recorded at 38.22% and seen at 14.44% in the previous month. Mizuho set a $21.00 price target on shares of Carrizo Oil & Gas and gave the stock a “hold” rating in a report on Friday, November 24th. (NASDAQ:CRZO) on Wednesday, February 24 with “Buy” rating. The firm earned “Buy” rating on Monday, June 26 by BMO Capital Markets. The firm has “Outperform” rating given on Friday, December 29 by Wedbush. (NYSE:CCS) earned “Buy” rating by Citigroup on Tuesday, August 8. Stifel Nicolaus maintained the shares of AEGN in report on Thursday, September 7 with “Hold” rating. Imperial Capital maintained the shares of CRZO in report on Wednesday, February 24 with “Outperform” rating.

Carrizo Oil & Gas, Inc., together with its subsidiaries, engages in the exploration, development, and production of gas and oil primarily in the United States. A beta of less than 1 means that the security is theoretically less volatile than the market. The firm holds interests in gas and oil plays, including Eagle Ford Shale in South Texas; the Delaware Basin in West Texas; the Niobrara Formation in Colorado; the Utica Shale in OH; and the Marcellus Shale in Pennsylvania. Its Current ratio for most recent quarter of 1.20.

Since August 28, 2017, it had 2 buys, and 2 insider sales for $1.45 million activity. Finally, Quantitative Systematic Strategies LLC acquired a new stake in Carrizo Oil & Gas in the fourth quarter valued at $235,000. The stock decreased 0.16% or $0.03 during the last trading session, reaching $18.56.

3D Systems Corporation (DDD) stock price traded at a gap of -0.09% from an average price of last twenty days and stands at a distance of 2.87% away from it’s an average price of recent fifty days. Goldman Sachs upgraded Carrizo Oil & Gas, Inc. (NASDAQ:CRZO) has declined 34.05% since February 21, 2017 and is downtrending. It has underperformed by 50.75% the S&P500.

Investors sentiment increased to 2.43 in 2017 Q3. Its down 0.31, from 1.31 in 2017Q2. The stock grabbed 18 new institutional investments totaling 330,443 shares while 5 institutional investors sold out their entire positions totaling 70,077 shares. Ameritas Prtnrs reported 0% stake. (NASDAQ:CRZO). Counselors Of Maryland Ltd Liability Corp invested in 0.97% or 1.11M shares. It also upped Blackhawk Network Holdings (NASDAQ:HAWK) stake by 106,929 shares and now owns 561,959 shares. Pub Employees Retirement Association Of Colorado invested in 453,604 shares or 0.06% of the stock.

Why Zion Oil & Gas, Inc. Empyrean Capital Partners Lp who had been investing in Carrizo Oil & Gas Inc for a number of months, seems to be bullish on the $1.51 billion market cap company. Shares of ZN moved upward with change of 66.47% to its 50-day Moving average. Howe And Rusling stated it has 0% in Carrizo Oil & Gas, Inc. Macroview Investment Mngmt Ltd Liability Com reported 2,000 shares. Wellington Management Grp Llp invested in 192,923 shares. Amalgamated Bank bought a new position in shares of Carrizo Oil & Gas during the 3rd quarter worth approximately $182,000. (NASDAQ:CRZO) for 149,991 shares. The company’s shares were given away at $1.99 per share worth to an income of some $49,881 on account of Van Brauman Martin.

Ratings analysis reveals 23% of Zions Bancorp’s analysts are positive.

For Carrizo Oil & Gas (NASDAQ:CRZO) out of the analyst recommendations 6 analysts recommend stock a Buy, 11 rate the stock Outperform, 7 analysts recommend to Hold the stock, 0 rate Underperform and 0 analysts recommend the stock a Sell.

Investors may be trying to decide if stocks will make new highs before the year is out, and whether or not the bull market will celebrate its 9th anniversary next year. ZN stock price revealed optimistic move of 47.94% comparing average price of last 200 days. ZION was included in 14 notes of analysts from October 6, 2016. RBC Capital Markets maintained it with “Buy” rating and $23.0 target in Thursday, November 9 report. Nine research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company. The rating was maintained by Raymond James on Tuesday, December 12 with “Buy”. (NASDAQ:CRZO) earned “Neutral” rating by Mizuho on Thursday, September 7.

Analysts await Methanex Corporation (NASDAQ:MEOH) to report earnings on April, 25. ZION’s profit will be $161.97 million for 16.76 P/E if the $0.82 EPS becomes a reality. Prudential Finance holds 0.01% of its portfolio in Aegion Corporation (NASDAQ:AEGN) for 259,386 shares. $248,498 worth of Celgene Corporation (NASDAQ:CELG) shares were sold by Curran Terrie.

Third Avenue Management Llc decreased Comerica Inc. Bedell Frazier Inv Counseling Ltd Company, a California-based fund reported 308,976 shares. The stock increased 0.73% or $0.29 during the last trading session, reaching $39.99.

Related Posts:

  • No Related Posts

Analysts See $-0.24 EPS for GenMark Diagnostics, Inc. (GNMK)

Aqr Capital Management Ltd Liability owns 23,204 shares. California Pub Employees Retirement Sys accumulated 0% or 50,700 shares. Alliancebernstein Limited Partnership holds 0% of its portfolio in GenMark Diagnostics, Inc. (NASDAQ:GNMK) for 49,300 shares. Deutsche Bank & Trust Ag holds …

February 21, 2018 – By Clifton Ray

 Analysts See $ 0.24 EPS for GenMark Diagnostics, Inc. (GNMK)
Investors sentiment decreased to 1.88 in Q3 2017. Its down 2.12, from 4 in 2017Q2. It dropped, as 11 investors sold GenMark Diagnostics, Inc. shares while 15 reduced holdings. 11 funds opened positions while 38 raised stakes. 56.57 million shares or 46.84% less from 106.41 million shares in 2017Q2 were reported.

Blair William & Com Il invested 0% in GenMark Diagnostics, Inc. (NASDAQ:GNMK). Fincl Bank Of Ny Mellon Corporation has invested 0% in GenMark Diagnostics, Inc. (NASDAQ:GNMK). Glenmede Na accumulated 1,000 shares. Cannell Peter B And Commerce Incorporated holds 0% of its portfolio in GenMark Diagnostics, Inc. (NASDAQ:GNMK) for 10,000 shares. Td Asset Mngmt accumulated 130,280 shares. Swiss Bancshares has 89,000 shares. Barclays Public Limited Company accumulated 1,181 shares or 0% of the stock. Citigroup has invested 0% in GenMark Diagnostics, Inc. (NASDAQ:GNMK). Goldman Sachs Group holds 0% or 82,260 shares in its portfolio. Aqr Capital Management Ltd Liability owns 23,204 shares. California Pub Employees Retirement Sys accumulated 0% or 50,700 shares. Alliancebernstein Limited Partnership holds 0% of its portfolio in GenMark Diagnostics, Inc. (NASDAQ:GNMK) for 49,300 shares. Deutsche Bank & Trust Ag holds 142,541 shares. Vanguard Grp Inc Inc has 0% invested in GenMark Diagnostics, Inc. (NASDAQ:GNMK). Granite Inv Partners Ltd Liability Corporation holds 0.05% of its portfolio in GenMark Diagnostics, Inc. (NASDAQ:GNMK) for 85,083 shares.

Since August 21, 2017, it had 0 insider buys, and 12 insider sales for $427,182 activity. Another trade for 848 shares valued at $4,350 was made by McNally James B. on Friday, February 2. Gleeson Michael sold $18,267 worth of stock. Another trade for 4,000 shares valued at $20,200 was sold by Stier Eric. 148 shares valued at $759 were sold by Kayyem Jon Faiz on Friday, February 2. $1,872 worth of stock was sold by Williams Jennifer Anne on Friday, February 2. 1,252 shares were sold by MASSARANY HANY, worth $6,423.

Analysts expect GenMark Diagnostics, Inc. (NASDAQ:GNMK) to report $-0.24 EPS on February, 27 after the close.They anticipate $0.03 EPS change or 11.11 % from last quarter’s $-0.27 EPS. After having $-0.28 EPS previously, GenMark Diagnostics, Inc.’s analysts see -14.29 % EPS growth. The stock increased 1.59% or $0.07 during the last trading session, reaching $4.46. About 149,209 shares traded. GenMark Diagnostics, Inc. (NASDAQ:GNMK) has risen 116.11% since February 22, 2017 and is uptrending. It has outperformed by 99.41% the S&P500.

GenMark Diagnostics, Inc. (NASDAQ:GNMK) Ratings Coverage

Among 6 analysts covering Genmark Diagnostics (NASDAQ:GNMK), 5 have Buy rating, 0 Sell and 1 Hold. Therefore 83% are positive. Genmark Diagnostics had 19 analyst reports since October 14, 2015 according to SRatingsIntel. The rating was downgraded by Raymond James on Friday, November 3 to “Market Perform”. On Wednesday, October 28 the stock rating was maintained by Needham with “Buy”. Cowen & Co upgraded GenMark Diagnostics, Inc. (NASDAQ:GNMK) on Friday, September 16 to “Outperform” rating. The rating was maintained by Needham on Friday, January 19 with “Buy”. The rating was maintained by Needham with “Buy” on Wednesday, August 30. The firm earned “Buy” rating on Monday, June 12 by Needham. As per Monday, June 12, the company rating was maintained by Canaccord Genuity. The rating was maintained by Canaccord Genuity on Friday, November 3 with “Buy”. Needham maintained it with “Buy” rating and $15 target in Tuesday, January 24 report. Canaccord Genuity maintained it with “Buy” rating and $14.0 target in Monday, October 30 report.

GenMark Diagnostics, Inc., a molecular diagnostics company, develops and commercializes molecular tests based on its proprietary eSensor electrochemical detection technology. The company has market cap of $244.39 million. The firm provides XT-8 instrument, and related diagnostic and research tests, as well as certain custom manufactured reagents that enable reference laboratories and hospitals to support a range of molecular tests with a workstation and disposable test cartridges. It currently has negative earnings. It offers diagnostic tests for use with its XT-8 system that includes respiratory viral panel, cystic fibrosis genotyping test, warfarin sensitivity test, and thrombophilia risk test, as well as HCV genotyping test and associated custom manufactured reagents, and 2C19 genotyping test.

More notable recent GenMark Diagnostics, Inc. (NASDAQ:GNMK) news were published by: Prnewswire.com which released: “ACT NOW: Monteverde & Associates PC Announces an Investigation of GenMark …” on November 12, 2017, also Globenewswire.com with their article: “GenMark Diagnostics Provides Preliminary Operational and Financial Results for …” published on January 09, 2018, Globenewswire.com published: “GenMark Diagnostics Schedules Fourth Quarter and Full Year 2017 Financial …” on February 13, 2018. More interesting news about GenMark Diagnostics, Inc. (NASDAQ:GNMK) were released by: Globenewswire.com and their article: “GenMark Diagnostics to Present at the JP Morgan 36th Annual Healthcare Conference” published on December 21, 2017 as well as Globenewswire.com‘s news article titled: “GenMark Diagnostics to Present at Upcoming Investor Conferences” with publication date: February 21, 2018.

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.

Related Posts:

  • No Related Posts